Next 10 |
home / stock / cort / cort articles
Monday, Corcept Therapeutics Incorporated (NASDAQ:CORT) released results from the open-label portion of the pivotal Phase 3 GRACE trial o...
Thursday, Corcept Therapeutics Incorporated (NASDAQ:CORT) released announced preliminary results from the prevalence phase of its ongoing...
In a new SEC filing on February 14, it was unveiled that Robb, Chief Business Officer at Corcept Therapeutics (NASDAQ:CORT), acquired stock options...
In a new SEC filing on February 14, it was unveiled that Hunt, Chief Scientific Officer at Corcept Therapeutics (NASDAQ:CORT), acquired stock optio...
A noteworthy insider acquisition was disclosed on February 14, as Lyon, Chief Accounting Officer at Corcept Therapeutics (NASDAQ:CORT), reported th...
A noteworthy insider acquisition was disclosed on February 14, as Guyer, Chief Development Officer at Corcept Therapeutics (NASDAQ:CORT), reported ...
Disclosed in a recent SEC filing, Joseph K Belanoff, Chief Executive Officer at Corcept Therapeutics (NASDAQ:CORT), made a strategic move by acquir...
MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the...
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday. Shares of Archer-Daniels-Midland Company...
News, Short Squeeze, Breakout and More Instantly...
Corcept Therapeutics Incorporated Company Name:
CORT Stock Symbol:
NASDAQ Market:
Monday, Corcept Therapeutics Incorporated (NASDAQ:CORT) released results from the open-label portion of the pivotal Phase 3 GRACE trial o...
A look at the top 10 most actives in the United States Moolec Science SA (MLEC) rose 85.7% to $2.6 on volume of 50,077,650 shares SuperCom Ltd. (SPCB) rose 46.0% to $0.3212 on volume of 37,315,721 shares AGBA Group Holding Limited (AGBA) rose 35.2% to $1.69 on volume of 26,672,582 shares ...
MENLO PARK, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of t...